JP4302986B2 - 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 - Google Patents

細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 Download PDF

Info

Publication number
JP4302986B2
JP4302986B2 JP2002569071A JP2002569071A JP4302986B2 JP 4302986 B2 JP4302986 B2 JP 4302986B2 JP 2002569071 A JP2002569071 A JP 2002569071A JP 2002569071 A JP2002569071 A JP 2002569071A JP 4302986 B2 JP4302986 B2 JP 4302986B2
Authority
JP
Japan
Prior art keywords
radiation
ionizing radiation
cells
exposure
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002569071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525908A5 (enExample
JP2004525908A (ja
Inventor
イー．レディー プレムクマル
エム．ヴィ．レディー ラマナ
シー．コゼンツァ スティーブン
ヘルソン ロレンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2004525908A publication Critical patent/JP2004525908A/ja
Publication of JP2004525908A5 publication Critical patent/JP2004525908A5/ja
Application granted granted Critical
Publication of JP4302986B2 publication Critical patent/JP4302986B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002569071A 2001-02-28 2002-02-28 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法 Expired - Lifetime JP4302986B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28
PCT/US2002/006107 WO2002069892A2 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES

Publications (3)

Publication Number Publication Date
JP2004525908A JP2004525908A (ja) 2004-08-26
JP2004525908A5 JP2004525908A5 (enExample) 2005-12-22
JP4302986B2 true JP4302986B2 (ja) 2009-07-29

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002569071A Expired - Lifetime JP4302986B2 (ja) 2001-02-28 2002-02-28 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法

Country Status (10)

Country Link
US (1) US6667346B2 (enExample)
EP (1) EP1370253B8 (enExample)
JP (1) JP4302986B2 (enExample)
KR (1) KR100850331B1 (enExample)
AT (1) ATE406881T1 (enExample)
AU (1) AU2002305942B2 (enExample)
CA (1) CA2439288C (enExample)
DE (1) DE60228692D1 (enExample)
IL (2) IL157541A0 (enExample)
WO (1) WO2002069892A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461915T1 (de) 2000-10-05 2010-04-15 Univ Temple Substituierte (e)-styrylbenzylsulfone zur behandlung proliferativer erkrankungen
AU2003213661A1 (en) * 2002-02-28 2003-09-09 Onconova Therapeutics, Inc. Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
EA008736B1 (ru) * 2002-02-28 2007-08-31 Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Аминозамещенные (e)-2,6-диалкоксистирил-4-замещенные-бензилсульфоны для лечения пролиферативных расстройств
JP5196787B2 (ja) * 2003-11-14 2013-05-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 増殖性疾患を治療するためのα，β−不飽和スルホキシド
EP1694322A2 (en) * 2003-11-26 2006-08-30 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
EP3138832A1 (en) 2004-03-16 2017-03-08 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
WO2006025924A2 (en) 2004-06-24 2006-03-09 Temple University Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
ATE536101T1 (de) * 2005-01-05 2011-12-15 Univ Temple Behandlung heilmittelresistenter proliferativer erkrankungen
SI1896401T1 (sl) * 2005-02-25 2013-07-31 Temple University - Of The Commonwealth System Of Higher Education Sinteza nenasičenih sulfidov, sulfonov, sulfoksidov in sulfonamidov
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007016201A2 (en) 2005-07-29 2007-02-08 Onconova Therapeutics, Inc. FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
WO2008105808A2 (en) * 2006-07-28 2008-09-04 Onconova Therapeutics, Inc. FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
WO2008027049A1 (en) 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008076270A2 (en) * 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
CA2738925A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
WO2010051127A2 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
EP2373993B1 (en) * 2008-12-16 2015-08-05 Onconova Therapeutics, Inc. Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
WO2010132725A2 (en) 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
CN104320971A (zh) * 2010-03-24 2015-01-28 安哥洛华治疗公司 用于预防和治疗创伤的组合物和方法
ES2546672T3 (es) 2010-03-26 2015-09-25 Onconova Therapeutics, Inc. Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
CN103501789A (zh) 2010-11-17 2014-01-08 北卡罗来纳大学查珀尔希尔分校 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血
CN104812382A (zh) 2012-09-20 2015-07-29 坦普尔大学 取代的烷基二芳基衍生物、制备方法和用途
WO2014144847A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
CA2936036C (en) * 2014-01-06 2022-08-16 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2017023912A1 (en) 2015-08-03 2017-02-09 Temple University - Of The Commonwealth System Of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114748622B (zh) 2017-10-05 2024-09-24 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
EP4001263B1 (en) * 2019-07-18 2024-03-27 Huaxiashengsheng Pharmaceutical Beijing Co., Ltd. Carbamate-substituted styryl sulfone compound, preparation method, and application thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4294217B2 (ja) 1997-10-03 2009-07-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
US6201154B1 (en) 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
ATE298234T1 (de) 1999-04-02 2005-07-15 Univ Temple (e)-styrylsulfone als krebsbestreitende mittel
JP2002541101A (ja) * 1999-04-02 2002-12-03 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
AU2001251391A1 (en) * 2000-04-06 2001-10-23 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
EP1379508B9 (en) * 2001-02-28 2011-02-09 Temple University - Of The Commonwealth System of Higher Education N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Also Published As

Publication number Publication date
DE60228692D1 (de) 2008-10-16
EP1370253B8 (en) 2008-11-26
WO2002069892A3 (en) 2002-11-07
EP1370253B1 (en) 2008-09-03
US20030060505A1 (en) 2003-03-27
EP1370253A4 (en) 2005-08-17
KR100850331B1 (ko) 2008-08-04
KR20030086596A (ko) 2003-11-10
ATE406881T1 (de) 2008-09-15
EP1370253A2 (en) 2003-12-17
CA2439288A1 (en) 2002-09-12
IL157541A (en) 2010-05-31
US6667346B2 (en) 2003-12-23
AU2002305942B2 (en) 2006-10-26
CA2439288C (en) 2011-08-09
IL157541A0 (en) 2004-03-28
JP2004525908A (ja) 2004-08-26
WO2002069892A2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
JP4302986B2 (ja) 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法
AU2002305942A1 (en) Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
JP4171656B2 (ja) Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途
JP2012504645A (ja) 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
JP2009541222A (ja) 核、日光、および他の放射線誘発の組織損傷の予防
JP2018513123A (ja) Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
AU2002306604A1 (en) N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
CN107823211A (zh) 葡萄糖胺在制备电离辐射致放射性肺损伤防治药物中的应用
US20250177368A1 (en) Radiation mitigator and method of use thereof
JP5196787B2 (ja) 増殖性疾患を治療するためのα，β−不飽和スルホキシド
Geldof et al. Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells
JP5553306B2 (ja) 放射線障害防護剤
JPWO2019087957A1 (ja) 放射性抗腫瘍剤
Patel et al. Overcoming Melphalan Resistance by Targeting Crucial DNA Repair Pathways in Multiple Myeloma
KR20190074480A (ko) 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료를 위한 약제학적 조성물
JP2007512378A (ja) 放射線障害から保護するためのβ−ラパコンの使用
JP6099043B2 (ja) 造血又は腸管放射線障害防護剤
Hovdenak Acute radiation proctitis. A clinical, histopathological and histochemical study
WO2022016231A1 (en) Methods of treatment
Puukila Cardiac oxidative stress and antioxidant status in response to radiation and monocrotaline induced cardiac dysfunction
JP2023503127A (ja) 黒色腫の発症を予防する方法
CN110354257A (zh) 鸟苷三磷酸环化水解酶1的应用及药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081126

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090331

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090423

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120501

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4302986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120501

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130501

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140501

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term